Almawash S
Cancers (Basel). 2025; 17(5).
PMID: 40075727
PMC: 11899125.
DOI: 10.3390/cancers17050880.
Karabatic Knezovic S, Knezovic D, Ban J, Matana A, Puizina Ivic N, Glavina Durdov M
Medicina (Kaunas). 2025; 61(2).
PMID: 40005446
PMC: 11857809.
DOI: 10.3390/medicina61020330.
Abdo E, Ajib I, El Mounzer J, Husseini M, Kalaoun G, Matta T
Inflamm Res. 2025; 74(1):41.
PMID: 39960501
DOI: 10.1007/s00011-025-02008-5.
Knickmeier C, Noubissi Nzeteu G, Gibbs B, Hoogwater F, Nijkamp M, Bockhorn M
Front Immunol. 2025; 16:1495907.
PMID: 39958335
PMC: 11825744.
DOI: 10.3389/fimmu.2025.1495907.
Phulari R, Solanki B
J Oral Maxillofac Pathol. 2025; 28(4):641-650.
PMID: 39949682
PMC: 11819625.
DOI: 10.4103/jomfp.jomfp_327_22.
Immunotherapy-Related Hypophysitis: A Narrative Review.
Di Stasi V, La Sala D, Cozzi R, Scavuzzo F, De Geronimo V, Poggi M
Cancers (Basel). 2025; 17(3).
PMID: 39941803
PMC: 11815778.
DOI: 10.3390/cancers17030436.
Investigating the functional and structural effect of non-synonymous single nucleotide polymorphisms in the cytotoxic T-lymphocyte antigen-4 gene: An in-silico study.
Kamal M, Shantanu K, Teeya S, Rahman M, Hasan A, Chivers D
PLoS One. 2025; 20(1):e0316465.
PMID: 39854591
PMC: 11759363.
DOI: 10.1371/journal.pone.0316465.
Engineered ipilimumab variants that bind human and mouse CTLA-4.
Robison B, Diong S, Kumar A, Moon T, Chang O, Chau B
MAbs. 2025; 17(1):2451296.
PMID: 39849917
PMC: 11776466.
DOI: 10.1080/19420862.2025.2451296.
Weight and Blood-Based Markers of Cachexia Predict Disability, Hospitalization and Worse Survival in Cancer Immunotherapy Patients.
Tran S, Forrest N, Guggilla V, Perottino G, Johnson J, Sosman J
J Cachexia Sarcopenia Muscle. 2025; 16(1):e13685.
PMID: 39817619
PMC: 11736629.
DOI: 10.1002/jcsm.13685.
Immune Checkpoint Inhibitor-Associated Cutaneous Adverse Events: Mechanisms of Occurrence.
Eshaq A, Flanagan T, Ba Abbad A, Makarem Z, Bokir M, Alasheq A
Int J Mol Sci. 2025; 26(1.
PMID: 39795946
PMC: 11719825.
DOI: 10.3390/ijms26010088.
Anti-CTLA-4 generates greater memory response than anti-PD-1 via TCF-1.
Mok S, Liu H, Agac Cobanoglu D, Anang N, Mancuso J, Wherry E
Proc Natl Acad Sci U S A. 2025; 122(2):e2418985122.
PMID: 39786926
PMC: 11745370.
DOI: 10.1073/pnas.2418985122.
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment.
Wei J, Li W, Zhang P, Guo F, Liu M
Mol Cancer. 2024; 23(1):279.
PMID: 39725966
PMC: 11670468.
DOI: 10.1186/s12943-024-02179-5.
Into the Future: Fighting Melanoma with Immunity.
Corica D, Bell S, Miller P, Kasperbauer D, Lawler N, Wakefield M
Cancers (Basel). 2024; 16(23).
PMID: 39682188
PMC: 11640241.
DOI: 10.3390/cancers16234002.
Immuno-oncologic profiling by stage-dependent transcriptome and proteome analyses of spontaneously regressing canine cutaneous histiocytoma.
Loriani Fard A, Haake A, Jovanovic V, Andreotti S, Hummel M, Hempel B
PeerJ. 2024; 12:e18444.
PMID: 39619201
PMC: 11606323.
DOI: 10.7717/peerj.18444.
2q33 Deletions Underlying Syndromic and Non-syndromic CTLA4 Deficiency.
Brakta C, Tabet A, Puel M, Pacault M, Stolzenberg M, Goudet C
J Clin Immunol. 2024; 45(1):46.
PMID: 39578275
DOI: 10.1007/s10875-024-01831-5.
Differential chromatin accessibility and transcriptional dynamics define breast cancer subtypes and their lineages.
Iglesia M, Jayasinghe R, Chen S, Terekhanova N, Herndon J, Storrs E
Nat Cancer. 2024; 5(11):1713-1736.
PMID: 39478117
PMC: 11584403.
DOI: 10.1038/s43018-024-00773-6.
Internal regulation between constitutively expressed T cell co-inhibitory receptors BTLA and CD5 and tolerance in recent thymic emigrants.
Adegoke A, Thangavelu G, Chou T, Petersen M, Kakugawa K, May J
Open Biol. 2024; 14(10):240178.
PMID: 39471840
PMC: 11521602.
DOI: 10.1098/rsob.240178.
T lymphocyte‑related immune response and immunotherapy in gastric cancer (Review).
Zhang Z, Zhang W, Liu X, Yan Y, Fu W
Oncol Lett. 2024; 28(5):537.
PMID: 39319215
PMC: 11421013.
DOI: 10.3892/ol.2024.14670.
Combination anti-PD-1 and anti-CTLA-4 therapy generates waves of clonal responses that include progenitor-exhausted CD8 T cells.
Wang K, Coutifaris P, Brocks D, Wang G, Azar T, Solis S
Cancer Cell. 2024; 42(9):1582-1597.e10.
PMID: 39214097
PMC: 11387127.
DOI: 10.1016/j.ccell.2024.08.007.
Immune Checkpoint Inhibitors for Pediatric Cancers: Is It Still a Stalemate?.
Jaing T, Wang Y, Chiu C
Pharmaceuticals (Basel). 2024; 17(8).
PMID: 39204096
PMC: 11357301.
DOI: 10.3390/ph17080991.